Global Oligonucleotides Synthesis Market to Expand at a CAGR of 11.3% During the Forecast Period (2020-2025)

Companies in the Oligonucleotides Synthesis Market are facing issues in keeping their production facilities fully functional due to shortage of staff and resources amidst the COVID-19 (Coronavirus) outbreak. Get a hands-on over key drivers and threats to the Oligonucleotides Synthesis Market to make your company future-ready post the pandemic. Avails out reports for exciting prices to learn new opportunities that companies can capitalize on during and after the Coronavirus crisis.

Integrated DNA Technologies, for instance, is a company extensively engaged in the development of oligonucleotides up to 200 base length, suitable for usage in manufacturing mini-genes. Based on these trends, the global oligonucleotide synthesis market is poised to propel towards positive growth, registering a staggering CAGR of 11.3% during the forecast period (2020-2025).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4853

Key Takeaways of the Global Oligonucleotide Synthesis Market Study

• By product, synthesized oligonucleotides are anticipated to find substantial application. Suitability in therapeutics for treating neurodegenerative diseases and cancer is anticipated to heighten market prospects. The segment is projected to capture more than 3/5^th of the total market share.
• Application in therapeutics is anticipated to expand at a stellar rate of 18.4% through 2025. Increased availability of therapies such as antisense oligonucleotides and nucleic acid aptamers for treating dystrophy, cancer, and other neurological conditions is anticipated to drive the market growth.
• Use of oligonucleotide synthesis in research segment is poised to record a significant growth rate over the forecast period. Rising potential usage of oligonucleotides in polymerase chain reaction (PCR) and next generation sequencing is anticipated to bolster growth prospects of key market players.
• Biotechnology & pharmaceutical companies emerge as key end users of oligonucleotide synthesis and are poised to register a robust CAGR of 15.5% through 2025. Increased FDA approvals for oligonucleotides as therapeutic agents, robust R&D pipeline of pharmaceutical and biotechnology companies, and a rise in clinical trials for new diseases are important growth drivers.
• Asia Pacific is an emerging hub for the global oligonucleotide synthesis market. This is attributable to increasing life science research and development, government initiatives, grants and funds, and designation of research zones. The regional market is projected to expand at a CAGR of 12.5% during the forecast period.
• North America continues to maintain its lead in the global market, driven by rapid expansion of the life science industry, presence of market players concentrating on oligonucleotides as therapeutic agents such as antisense and RNAi therapeutics, and strong focus on genetics and genomics in research diagnostics.

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4853

 

Product Development – A Key Growth Stimulant for Market Players

The global oligonucleotide market consists of the following market players: Thermo Fisher Scientific Corporation, Integrated DNA Technologies, Inc., Sigma-Aldrich Corporation (a part of Merck KGaA), GE Healthcare, Kaneka Eurogentec S.A., TriLink Biotechnologies, LLC (Maravai Life Sciences), BioAutomation and ATDBio Ltd., to name a few.

Integrated DNA Technologies is the leader in the global oligonucleotide synthesis market. It supplies custom oligonucleotides for academic and pharmaceutical research as well as pharmaceutical drug development. It has a strong focus on delivering excellent customer service. Its products include the Ultramer DNA Oligos and Primer Mix DNA Plate Oligos.

For comprehensive insights on this market adoption, ask an analyst here- https://www.factmr.com/connectus/sample?flag=AE&rep_id=4853

BioAutomation, another player, provides automation solutions to research institutes to enable them to conduct studies surrounding advancements in the biotechnology industry. Products offered by BioAutomation include the MerMade 48X oligonucleotide synthesizer, the MerMade 96E oligonucleotide synthesizer and the MerMade 192E/R/X oligonucleotide synthesizers.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com